Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)
Systemic Lupus Erythematosus Disease Activity Index 2000 · Also known as: SLEDAI, SLEDAI-2K, SLE Disease Activity Index
The SLEDAI is a comprehensive clinician-assessed measure of systemic lupus erythematosus (SLE) disease activity, capturing manifestations across multiple organ systems (cutaneous, renal, neuropsychiatric, hematologic, and serological). Introduced by Bombardier et al. (1992) and refined as SLEDAI-2K by Gladman et al. (2002), SLEDAI uses weighted scoring of 24 clinical and laboratory features to quantify overall SLE activity. It is the most widely used outcome measure in SLE research and clinical trials, enabling standardised assessment of disease progression, flare prediction, and treatment response in this complex multisystem disease.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
SLEDAI is the primary outcome measure for SLE disease activity assessment in research, clinical trials, and clinical practice. Use at baseline to establish disease severity, then at regular intervals (every 4–12 weeks during active disease, 3–6 months during stable remission) to monitor therapy response and predict flares. SLEDAI is particularly valuable for: (1) clinical trial efficacy assessment of new immunosuppressive therapies; (2) predicting lupus nephritis flares (rising SLEDAI, low complement, rising anti-dsDNA predict renal flare); (3) monitoring patients with multi-organ involvement where global activity assessment is critical; (4) organ-specific outcome tracking (e.g., renal SLEDAI scores for nephritis trials); (5) long-term prognostic assessment (high SLEDAI predicts cumulative organ damage). SLEDAI is validated for adults with SLE diagnosis; modified pediatric versions exist for childhood-onset SLE.
Strengths & limitations
- Comprehensive multisystem assessment; captures disease manifestations across all major organ systems affected by SLE, from cutaneous to neuropsychiatric to renal.
- Weighted scoring reflects clinical severity; major manifestations (renal, neuropsychiatric) carry higher weights than minor features (photosensitivity, oral ulcers), improving clinical relevance.
- Extensively validated in large SLE cohorts and pivotal trials (LUNAR, BELONG, SEAQUENCE); standardised, reproducible, and internationally recognized.
- Predictive validity for organ damage: elevated SLEDAI predicts long-term cumulative damage index and progression to end-stage renal disease.
- Responsive to change; MCID ≈ 3 points; sensitive to therapy effects, particularly immunosuppressive escalation or remission.
- Integrates clinical and laboratory features; combines bedside assessment with objective serology (anti-dsDNA, complement) and urinalysis.
- Well-suited to complex multisystem disease; enables single-number summary of heterogeneous manifestations, facilitating communication and research.
- Clinician-dependent scoring; inter-rater variability in assessing features like photosensitivity or psychosis can reduce reliability without standardised definitions or training.
- Relies on patient recall over preceding 10 days; patients may not accurately report symptoms (e.g., photosensitivity, headache), introducing recall bias.
- Does not capture functional impact or quality of life; high SLEDAI may reflect active inflammation but may not correlate with patient-perceived burden.
- Immune-mediated features (low complement, anti-dsDNA elevation) are weighted equally with clinical manifestations; serological changes may precede symptoms by weeks, creating discordance.
- Limited sensitivity to cumulative damage (SLEDAI score is activity-based, not damage-based); structural kidney disease, retinal damage, and CNS scars do not contribute to SLEDAI.
- Ceiling effects in very severe disease; SLEDAI cannot distinguish among extreme activity states.
- SLEDAI-2K retains features from original 1992 SLEDAI; some features (e.g., haematuria with haematologic casts) may be scored redundantly or with unclear distinction.
Frequently asked
What does a SLEDAI score of 15 mean?
A SLEDAI of 15 indicates high disease activity (11–19 range). This suggests significant inflammation across one or more organ systems. Most SLE patients with SLEDAI ≥11 warrant escalation of immunosuppressive therapy if not already on aggressive treatment. Identify specific organ involvement (e.g., renal proteinuria, CNS seizures) to target therapy.
What is the difference between SLEDAI and SELENA-SLEDAI?
SLEDAI-2K is the 24-feature clinician-assessed index used in research and trials. SELENA-SLEDAI adds eight patient-reported items (e.g., weight gain, alopecia, vaginal ulcers) for enhanced clinical utility. Both are valid; SLEDAI-2K is preferred for trials due to standardisation; SELENA-SLEDAI is more practical for busy clinics where patient input is valued.
Can I use SLEDAI to diagnose lupus?
No. SLEDAI measures disease activity in patients with established SLE diagnosis. Diagnosis requires ACR/EULAR SLE classification criteria (serology, clinical features, complement, labs). SLEDAI is a monitoring tool for known SLE.
What if my SLEDAI is 0 but I still feel unwell?
SLEDAI = 0 indicates no acute inflammatory features over the preceding 10 days, but does not capture: (1) functional limitation from previous organ damage (e.g., renal scarring, chronic kidney disease); (2) chronic pain or fatigue independent of inflammation; (3) medication side effects; (4) comorbid conditions. Consider SLICC Damage Index (cumulative damage), functional assessment, and screening for depression or other non-inflammatory causes.
What does low complement (C3, C4) in SLEDAI mean?
Low serum C3 or C4 is scored +4 in SLEDAI and reflects immune complex deposition and consumption. Low complement is associated with active vasculitis and lupus nephritis. Combined with rising anti-dsDNA and declining SLEDAI, low complement predicts imminent renal or multi-organ flare. Serial monitoring is important.
How often should SLEDAI be assessed?
Baseline SLEDAI establishes disease severity. During active disease or flare, assess every 2–4 weeks to monitor response to therapy escalation. Once stable remission is achieved (SLEDAI ≤4, stable serology), assess every 3–6 months. Some guidelines recommend more frequent monitoring in high-risk patients (prior lupus nephritis, CNS disease).
Can anti-dsDNA and low complement rise without a flare?
Yes. Serological changes (anti-dsDNA rise, complement decrease) may precede clinical flare by weeks. Conversely, some patients have persistently abnormal serology without clinical disease activity ('serologically active clinically quiescent' state). SLEDAI should be integrated with clinical features and trends rather than serology alone.
What is the target SLEDAI for remission?
Complete remission is defined as SLEDAI = 0 off all medications or on low-dose prednisone (≤7.5 mg/day) with stable serology. Low disease activity is SLEDAI ≤4. Many SLE patients do not achieve SLEDAI = 0; the target in clinical practice is often SLEDAI <4 on acceptable therapy doses and without organ damage progression.
Sources
- Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. The Journal of Rheumatology. 2002;29(2):288-291. link ↗
- Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis & Rheumatism. 1992;35(6):630-640. DOI: 10.1002/art.1780350606 ↗
How to cite this page
ScholarGate. (2026, June 3). Systemic Lupus Erythematosus Disease Activity Index 2000. ScholarGate. https://scholargate.app/en/rheumatology/sledai
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Bath Ankylosing Spondylitis Disease Activity IndexRheumatology↔ compare
- Disease Activity Score 28Rheumatology↔ compare
- Routine Assessment of Patient Index Data 3Rheumatology↔ compare